The plant will process high potency compounds into medicines preclinical safety studies, as well as for Phase I and II trials.
Dosage forms produced at the 17,000 sq ft factory, in Nutley, include tablets, capsules, powders , suspensions and solutions.
“This is a vitally important milestone for the Nutley site as well as Pharmaceutical Research and Early Development at Roche,” Waseem Malick, VP of pharmaceutical & analytical R&D at Roche said.
“It enables continued support of our portfolio, and is another example of Roche’s commitment to Nutley as a major research center for Roche.”